Loading…
HCM
HUTCHMED (China) Ltd
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 44842L103
$14.28-0.63%Price as of Oct 23, 00:53 UTC · updated once a day, after the close
At a glance
HUTCHMED (China) Ltd (HCM) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Hong Kong, Hong Kong and has 1,790 employees. The company is worth $2.48B and trades at 142.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $548.51M in fiscal 2025, down 13.0% from the year before. Net income was $456.91M. The share price is 12.6% below its 52-week high of $16.33. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $1.4M. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $2.48B
- P/E
- 142.8x
- Forward P/E
- 55.1x
- P/B
- 2.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.10
- ROE
- 1.46%
- Profit margin
- 3.26%
- Revenue growth
- +0.20%
- Beta
- 0.36
- 52-week high
- $16.33
- 52-week low
- $9.77
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Renaissance TechnologiesHeldRenaissance Technologies · Q2 2026$1.4M130.2K shares · 0.0% of portfolio
- Two SigmaHeldTwo Sigma Investments · Q2 2026$680.55K63.25K shares · 0.0% of portfolio
Ken GriffinHeldCitadel Advisors · Q2 2026$409.54K38.06K shares · 0.0% of portfolio- Israel EnglanderHeldMillennium Management · Q2 2026$284.28K26.42K shares · 0.0% of portfolio
Price over time
▼ -58.5% over 5Y.
today you would have $477.57▼ -52.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $13.33 | $14.41 | $18.11 | $14.78 | |
| P/E | 30.2x | 5.0x | 72.0x | 30.2x | — |
| P/S | 20.2x | 20.9x | 19.5x | 18.4x | 29.3x |
| P/B | 18.3x | 9.3x | 16.2x | 21.2x | 20.5x |
| EPS | $2.65 | $0.20 | $0.60 | -$2.15 | |
| Profit margin | 9.01% | 83.30% | 5.99% | 12.03% | -84.62% |
| ROE | 9.38% | 36.91% | 4.96% | 13.80% | -59.12% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$4.04
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$2.50
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Earnings
$2.43
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
$8.39
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $2.99 (avg. of 3)+Operating $8.39÷ 2 =$5.69
$5.69
4 methods answered, across 2 families.
$4.27
Room for errors in the reported numbers.
$14.28
-60.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZLABZai Lab Ltd | $22.04 | — | 4.1x | 0.00% | -26.91% | $2.47B |
| TMDXTransMedics Group, Inc. | $72.06 | 18.8x | 4.8x | 0.00% | 36.28% | $2.5B |
| GRDNGuardian Pharmacy Services, Inc. | $39.47 | 38.3x | 10.2x | 0.00% | 30.42% | $2.5B |
| ADMAADMA Biologics Inc | $10.95 | 15.6x | 6.0x | 0.00% | 41.90% | $2.45B |
| CLOVClover Health Investments Corp | $4.73 | — | 6.7x | 0.00% | -5.10% | $2.51B |
| SUPNSupernus Pharmaceuticals Inc | $42.07 | — | 2.4x | 0.00% | -10.49% | $2.45B |
About the company
- 1,790
- Hong Kong, Hong Kong